IgA nephropathy trials in South Korea

In South Korea 12 Also abroad 92

12 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Where
Seoul
Age
2 years to 18 years
People
28 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07498335
Phase 3Taking people
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Where
Seongnam-si, Seoul, Suwon, Yongin-si
Age
18 years and over
People
347 worldwide
Run by
Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00
Phase 2Taking people
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Where
Anyang-si, Seongnam-si, Seoul, Suwon
Age
18 years to 60 years
People
30 worldwide
Run by
Jade Biosciences, Inc.
See details and how to joinNCT07541287
Phase 2Taking people
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Where
Seoul
Age
18 years and over
People
32 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00
Phase 2Taking people
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Where
Cheonan, Daegu, Gyeonggi-do, Seoul, Wŏnju
Age
18 years and over
People
45 worldwide
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06989359
Phase 3Taking people
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Where
Anyang-si, Busan, Seongnam-si, Seoul, Suwon
Age
18 years and over
People
454 worldwide
Run by
Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Bundang Gu, Busan, Cheongju-si, Seoul, Taegu
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
Phase 3Taking people
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Where
Cheonan, Guri-si, Seongnam-si, Seoul
Age
18 years to 100 years
People
220 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06858319
Phase 2Taking people
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Where
Anyang, Busan, Seongnam-si, Seoul, Soeul, Suwon
Age
18 years to 75 years
People
96 worldwide
Run by
Walden Biosciences
See details and how to joinNCT06466135
Phase 3Taking people
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Where
Seoul
Age
2 years to 18 years
People
36 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00
Phase 2/3Enrolling by invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Where
Anyang, Busan, Daegu, Gwangju, Hwaseong-si, Seongnam, Seoul
Age
18 years and over
People
600 worldwide
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659
No phaseTaking people
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Where
Chuncheon, Daegu, Seoul
People
3,000
Run by
Seoul National University Hospital
See details and how to joinNCT03929887